NCT06516510View on ClinicalTrials.gov

A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

August 15, 2025

Study Completion Date

August 15, 2025

Conditions
Metastatic Prostate Cancer
Interventions
DRUG

lutetium (177Lu) rhPSMA 10.1 and Pluvicto®

Radiopharmaceutical

Trial Locations (6)

28027

Clinica Universidad de Navarra, Madrid

28050

Centro Integral Oncologico Clara Campal, Madrid

30322

Emory University Hospital, Atlanta

31008

Clinica Universidad de Navarra - Pamplona, Pamplona

33165

Biogenix Molecular LLC, Miami

6525GA

Radboud UMC, Nijmegen

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

Blue Earth Therapeutics Ltd

INDUSTRY

NCT06516510 - A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter